QualityStocks would like to highlight Northwest Biotherapeutics (OTCBB: NWBO), a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The company is developing dendritic cell-based vaccines. The company’s lead clinical trial is a 240-patient trial in newly diagnosed Glioblastoma multiforme (“GBM”), the most aggressive and lethal form of brain cancer. The company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers, and has conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.
In the company’s news yesterday,
Northwest Biotherapeutics announced its partnership with King’s Health Partners, in which the companies will manufacture and deliver a new treatment for patients with brain cancer as part of its ongoing 240-patient clinical trial for Glioblastoma multiforme (GBM), the most fatal form of brain cancer.
Per the arrangement, specialists at King’s College London will manufacture Northwest’s immune therapy treatment, DCVax®, for the clinical trial, which will take place at King’s College Hospital NHS Foundation Trust in London.
Among several anticipated benefits, the collaboration generates additional manufacturing capacity and flexibility for DCVax without requiring capital investment by Northwest.
“We are excited about partnering with such prestigious institutions as King’s College London and King’s College Hospital,” Linda Powers, CEO of Northwest stated in the press release. “This partnership can help accelerate our brain cancer clinical trials, and also help extend lives through compassionate use treatments for other patients while the trials are ongoing. This partnership also expands our manufacturing capacity and flexibility in a highly cost effective way – a great arrangement both for patients and for our programs.”
The collaboration enables King’s College Hospital to join Northwest’s ongoing clinical trial for GBM brain cancer, which is currently taking place at more than 30 clinical trial sites across the U.S. Northwest reports that the partnership also allows for the treatment of patients on a compassionate use basis, specifically for those who do not fully meet the criteria to enroll on the clinical trial, but may benefit from the treatment.
“We are pleased to be leading the way in bringing these novel immune therapies to patients in the UK,” stated Dr. Ashkan Keyoumars, a specialist, neurosurgeon, associate professor in Neurosurgery, and lead for King’s College Hospital’s neuro-oncology department. “Brain cancers are some of the most lethal cancers, and there is a great need for new and better treatments. The positive data from the phase I clinical trials in the U.S. were very encouraging in delaying disease progression and extending survival times, without significant toxic side effects. We are hopeful that similar results will be seen in the large, randomized clinical trial which we are now helping to bring to the UK.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
